pmid,title,journal,year,drug,disease
40934429,Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.,The Journal of clinical investigation,2025,Molnupiravir,SARS-CoV-2
40933128,Isolation of a SARS-CoV-2 strain from pediatric patients in South Korea: biologic and genetic characterization.,Frontiers in microbiology,2025,Molnupiravir,SARS-CoV-2
40913022,Development of GFP-expressing infectious clones for PRRSV using TAR cloning for antiviral drug screening.,Npj viruses,2025,Molnupiravir,SARS-CoV-2
40908598,"Inequities in COVID-19 antiviral dispensation in Victoria, Australia: A retrospective cohort study using linked data.",Australian journal of general practice,2025,Molnupiravir,SARS-CoV-2
40904363,Good syndrome presenting with multiple pulmonary infections: a case report involving metagenomic sequencing diagnosis.,Frontiers in medicine,2025,Molnupiravir,SARS-CoV-2
40900943,Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-beta-fluoro-4'-azidocytidine or azvudine.,NAR molecular medicine,2025,Molnupiravir,SARS-CoV-2
40872842,Pharmacological and Adjunctive Management of Non-Hospitalized COVID-19 Patients During the Omicron Era: A Systematic Review and Meta-Analysis.,Viruses,2025,Molnupiravir,SARS-CoV-2
40872778,SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations.,Viruses,2025,Molnupiravir,SARS-CoV-2
40872297,Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells.,"Pathogens (Basel, Switzerland)",2025,Molnupiravir,SARS-CoV-2
40787985,SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters.,Journal of virology,2025,Molnupiravir,SARS-CoV-2
40741617,Multitarget-based in silico screening from phytoactive compounds of Garcinia linii fighting toward severe acute respiratory syndrome coronavirus-2.,Tzu chi medical journal,2025,Molnupiravir,SARS-CoV-2
40736492,Top 20 Research Studies of 2024 for Primary Care Physicians.,American family physician,2025,Molnupiravir,SARS-CoV-2
40733581,"3,3'-Diindolylmethane Improves the Viral Pneumonia Outcomes After Influenza and SARS-CoV-2 Infection in Animal Models.",Viruses,2025,Molnupiravir,SARS-CoV-2
40733041,Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection.,Pharmaceutics,2025,Molnupiravir,SARS-CoV-2
40721474,SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study.,Nature communications,2025,Molnupiravir,SARS-CoV-2
40692086,Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays.,Toxicological sciences : an official journal of the Society of Toxicology,2025,Molnupiravir,SARS-CoV-2
40664729,Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations.,Scientific reports,2025,Molnupiravir,SARS-CoV-2
40659960,On degree-dependent topological study of line graph of some antiviral COVID-19 drugs.,"The European physical journal. E, Soft matter",2025,Molnupiravir,SARS-CoV-2
40605295,[Recurrent COVID-19 in a patient with Good's syndrome: a case report and literature review].,Zhonghua nei ke za zhi,2025,Molnupiravir,SARS-CoV-2
40600448,In Vitro Synergistic Antiviral Effects of beta-D-N4-hydroxycytidine and Teriflunomide in Combination against a Broad Range of RNA Viruses.,Journal of medical virology,2025,Molnupiravir,SARS-CoV-2
40575972,Successful salvage therapy of ruxolitinib on interstitial pneumonia after long COVID or post-COVID-19 syndrome with follicular lymphoma: two case reports and literature review.,Chinese clinical oncology,2025,Molnupiravir,SARS-CoV-2
40561865,Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N(4)-hydroxycytidine and inhibitors of CTP synthetase in cell culture.,Virology,2025,Molnupiravir,SARS-CoV-2
40549074,An in-vitro and in-silico approaches in exploring the molecular contact of COVID-19 antiviral drug molnupiravir with human serum albumin: effect of binding on protein structure.,Journal of computer-aided molecular design,2025,Molnupiravir,SARS-CoV-2
40543494,"Characterization of the tautomeric equilibrium of molnupiravir, an antiviral for the treatment of COVID-19.",Journal of pharmaceutical and biomedical analysis,2025,Molnupiravir,SARS-CoV-2
40509573,Structural Basis and Rational Design of Nucleotide Analogue Inhibitor Evading the SARS-CoV-2 Proofreading Enzyme.,Journal of the American Chemical Society,2025,Molnupiravir,SARS-CoV-2
40503169,Autophagy-enhancing strategies to promote intestinal viral resistance and mucosal barrier function in SARS-CoV-2 infection.,Autophagy reports,2025,Molnupiravir,SARS-CoV-2
40470763,Development of molnupiravir and peramivir loaded liposome formulations for combined antiviral therapy.,Pharmaceutical development and technology,2025,Molnupiravir,SARS-CoV-2
40419748,Construction and validation of a cell based reporter assay for identifying inhibitors of SARS coronavirus 2 RNA dependent RNA polymerase activity.,Scientific reports,2025,Molnupiravir,SARS-CoV-2
40409569,"Germline mutagenicity of molnupiravir and its active form, beta-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing.",Toxicology letters,2025,Molnupiravir,SARS-CoV-2
40409224,"Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand.",Journal of infection and public health,2025,Molnupiravir,SARS-CoV-2
40385477,Honeysuckle extracts as a potential inhibitor of SARS-CoV-2 infection.,Frontiers in pharmacology,2025,Molnupiravir,SARS-CoV-2
40383127,"Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.",The Lancet. Infectious diseases,2025,Molnupiravir,SARS-CoV-2
40359762,Electrochemical interpretations for the study of molnupiravir binding interactions with bovine serum albumin and DNA and molecular dynamics studies.,Biochemical and biophysical research communications,2025,Molnupiravir,SARS-CoV-2
40326978,Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials.,Journal of medical virology,2025,Molnupiravir,SARS-CoV-2
40278996,Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study.,Pharmacological reports : PR,2025,Molnupiravir,SARS-CoV-2
40267184,"Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M(Pro) inhibitors with potent in vivo efficacy.",Science advances,2025,Molnupiravir,SARS-CoV-2
40591755,,,2025,Molnupiravir,SARS-CoV-2
40204602,"Effectiveness of molnupiravir as early treatment for COVID-19 to prevent mortality and hospitalisation in high-risk adults: A systematic review and meta-analysis of randomised trials and real-world studies involving 1,612,082 patients.","Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi",2025,Molnupiravir,SARS-CoV-2
40204015,Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19.,American journal of kidney diseases : the official journal of the National Kidney Foundation,2025,Molnupiravir,SARS-CoV-2
40189329,Possible involvement of neuropeptide Y sub-receptor 1 (NPY-Y1) in the anti-viral response of SARS-CoV-2 infection in Syrian hamster.,"Biomedical research (Tokyo, Japan)",2025,Molnupiravir,SARS-CoV-2
40171981,Papaverine Targets STAT Signaling: A Dual-Action Therapy Option Against SARS-CoV-2.,Journal of medical virology,2025,Molnupiravir,SARS-CoV-2
40171487,3-Deazaguanosine inhibits SARS-CoV-2 viral replication and reduces the risk of COVID-19 pneumonia in hamster.,iScience,2025,Molnupiravir,SARS-CoV-2
40167341,A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.,The Journal of infectious diseases,2025,Molnupiravir,SARS-CoV-2
40152015,"Stability Indicating High Performance Liquid Chromatography Method Development, Validation, and Characterization of Forced Degradant Product by Liquid Chromatography-Mass Spectroscopy for Molnupiravir and Favipiravir.",Journal of chromatographic science,2025,Molnupiravir,SARS-CoV-2
40142561,Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case-Control Study (SAVALO Study).,Microorganisms,2025,Molnupiravir,SARS-CoV-2
40138219,Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.,Clinical and translational science,2025,Molnupiravir,SARS-CoV-2
40137701,Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study.,"Pathogens (Basel, Switzerland)",2025,Molnupiravir,SARS-CoV-2
40130852,The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.,Microbiology spectrum,2025,Molnupiravir,SARS-CoV-2
40104088,"Study anti-viral drugs for their efficiency against multiple SARS CoV-2 drug targets within molecular docking, molecular quantum similarity, and chemical reactivity indices frameworks.",F1000Research,2024,Molnupiravir,SARS-CoV-2
40099057,Real-World Treatment Outcomes in the First and Subsequent Coronavirus Disease 2019 (COVID-19) Hospital Clusters.,Cureus,2025,Molnupiravir,SARS-CoV-2
